1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Gland Pharma Ltd.

Gland Pharma Ltd.

2,858.70
INR
-65.60
(-2.24%)
70.41EPS
35.09P/E
407.78BMarket Cap
Nov 06Next Earn
Gland Pharma Ltd.
BSE:GLAND
(Bombay Stock Exchange)

Recent

price

2,858.70

P/E

ratio

35.09

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
96.77
122.07
157.5
216.58
267.08
218.17
342.54
338.93
388.63
409.32
Revenue per Share
19.66
27.67
47.33
63.07
73.81
47.44
46.9
42.4
62.35
70.44
Basic EPS, GAAP
7.16
3.03
31.01
23.8
16.37
8.56
36.34
31.6
32.59
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
20
18
- -
Dividend per Share
147.62
175.28
223.31
360.85
435.64
483.22
529.65
555.41
628.68
- -
Book Value per Share
147.62
175.28
223.31
360.85
434.87
482.51
508.13
533.93
604.25
- -
Tangible Book Value per Share
163
163
163
158
164
165
165
165
165
165
Basic Weighted Avg Shares
15,801
19,931
25,718
34,236
43,841
35,919
56,417
55,836
64,029
67,440
Sales/Revenue/Turnover
29
30.8
33.54
35.16
31.94
24.22
17.66
15.94
18.84
20.41
Operating Margin (%)
784
821
946
988
1,103
1,467
3,446
3,779
4,237
4,286
Depreciation Expense
3,211
4,519
7,729
9,970
12,117
7,810
7,725
6,985
10,273
11,606
Net Income, GAAP
35.98
34.16
22.16
25.31
25.14
25.94
31.79
34.27
29.86
28.17
Effective Tax Rate (%)
20.32
22.67
30.05
29.12
27.64
21.74
13.69
12.51
16.04
17.21
Profit Margin (%)
13,530
18,247
24,873
46,111
52,701
61,717
42,468
52,181
59,184
- -
Working Capital
66
60
50
47
45
37
1,412
1,072
932
- -
LT Debt
24,104
28,620
36,462
59,032
71,576
79,587
87,238
91,507
103,580
- -
Total Equity
- -
15
20.92
18.74
15.99
8.07
7.94
6.28
8.2
- -
Return on Invested Capital (%)
- -
17.16
23.85
20.9
18.58
10.39
9.23
7.79
10.43
- -
Return on Capital (%)
- -
17.14
23.75
20.88
18.55
10.33
9.26
7.82
10.53
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,904
- -
LT Borrowings
- -
699
- -
LT Finance Leases
- -
233
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
165
165
165
Market Capitalization
283,760
279,641
407,781

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
75,268
- -
Cash, Cash Equivalents & STI
- -
34,328
- -
Accounts Receivable, Net
- -
18,914
- -
Inventories
- -
17,439
- -
Total Current Liabilities
- -
16,084
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,904
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.03%
13.19%
Free Cash Flow
- -
47.78%
3.15%
Net Income, GAAP
- -
4.48%
47.07%
Sales/Revenue/Turnover
- -
16.14%
14.67%
Total Cash Common Dividend
- -
- -
-10%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
14,017
14,058
13,841
14,249
55,836
2026
15,056
- -
16,954
17,428
64,029
2027
18,003
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
8.73
9.93
12.42
11.32
42.4
2026
13.08
- -
15.87
22.26
62.35
2027
19.23
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
20
2026
- -
- -
- -
- -
18
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Gland Pharma Limited manufactures and markets complex generic injectable pharmaceuticals. The company produces sterile injectables including oncology and ophthalmics; complex injectables such as NCE-1s, First-to-File products and 505(b)(2) filings; formulations delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and specialized products like peptides, long-acting injectables, suspensions and hormonal therapies, with new delivery systems including pens and cartridges in development. It supplies products across therapeutic categories encompassing anti-infectives, anti-neoplastics, blood-related therapies, cardiac, gastrointestinal, hormones, neuro/CNS, pain and analgesics, respiratory, and vitamins, minerals and nutrients; and provides contract development and manufacturing organization (CDMO) services. Gland Pharma operates in over 60 countries including the United States, Europe, Canada, Australia, New Zealand, India and other markets. Founded in 1978 and headquartered in Hyderabad, India, the company functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd. Recent developments include a 250% expansion of GLP-1/cartridge production capacity from 40 million to 140 million units to address demand for diabetes and obesity treatments; launch of its first partnered GLP-1 product, Liraglutide; new product launches comprising four molecules in Q4 FY25; leadership changes with Srinivas Sadu appointed Executive Chairman and Shyamakant Giri as Chief Executive Officer in January 2025, alongside Satnam Singh Loomba joining as Chief Operating Officer in May 2024; and targeted annual revenue growth of 14-15% supported by expansions and a strengthened complex injectables pipeline.